SEC Form 4 · accession 0000899243-18-017071
LEXICON PHARMACEUTICALS, INC. · LXRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Artal Group S.A.
Director · 10% Owner
Artal International S.C.A.
Director · 10% Owner
Westend S.A.
Director · 10% Owner
Invus Public Equities Advisors, LLC
Director · 10% Owner
Invus Public Equities, L.P.
Director · 10% Owner
Invus Advisors, L.L.C.
Director · 10% Owner
Invus, L.P.
Director · 10% Owner
Pascal Minne
Director · 10% Owner
Administratiekantoor Westend Stichting
Director · 10% Owner
Artal International Management S.A.
Director · 10% Owner
Period of report
Jun 14, 2018
Accepted (ET)
Jun 18, 2018 · 6:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001062822
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3,F6,F7 | Jun 14, 2018 | P | 9,200 | $12.6589 | A | 2,970,094 | I | See Footnotes |
| Common StockF2,F3,F6,F7 | Jun 18, 2018 | P | 36,584 | $13.0641 | A | 3,006,678 | I | See Footnotes |
| Common StockF4,F6,F7 | holding | — | — | — | 21,321,961 | I | See Footnotes | |
| Common StockF5,F6,F7 | holding | — | — | — | 35,402,689 | I | See Footnotes |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- F2The shares reported as purchased on June 14, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.575 to $12.79 per share and the shares reported as purchased on June 18, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.95 to $13.10 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
- F3These securities are directly held by Invus Public Equities, L.P.
- F4These securities are directly held by Artal International S.C.A.
- F5These securities are directly held by Invus, L.P.
- F6Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.
- F7Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.
Remarks
Invus C.V. directly holds 4,321,214 shares of Issuer common stock. None of the Reporting Persons listed in Footnote 6 hereof have any beneficial or pecuniary interest for purposes of Section 16 of the Exchange Act in the shares of Issuer common stock directly held by Invus C.V. For purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization of the Issuer by virtue of Invus, L.P.'s right to designate certain members of the Issuer's board of directors pursuant to a stockholders' agreement between the Issuer and Invus, L.P.